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Accumulated studies have shown that ω-3 polyunsaturated fatty acids such as eicosapentaenoic acid 
(EPA) have protective roles against inﬂammatory responses such as hyperlipidemia,  diabetes mellitus 
(DM) and cardiovascular diseases.  Here we examined the eﬀects of administering EPA to hyperlipi-
demic patients and other patients undergoing cardiac surgery to determine whether this treatment 
would increase plasma EPA levels and to clarify the association between EPA treatment and adi-
ponectin production in hyperlipidemic patients.  We also assessed the eﬀect of preoperative EPA 
administration on postoperative adverse events such as postoperative atrial ﬁbrillation (POAF) and 
postoperative infection in the cardiac surgery patients.  The EPA administration signiﬁcantly increased 
the serum EPA concentrations in both patient populations (p＜0.001).  In the hyperlipidemic patients,  
the EPA administration signiﬁcantly increased plasma adiponectin levels (p＜0.05),  accompanied by a 
decrease in insulin resistance designated by the HOMA-IR (homeostasis model assessment of insulin 
resistance) score (p＜0.05) and Hs-CRP (high sensitivity C-reactive protein) value (p＜0.05).  In the car-
diac surgery patients,  no signiﬁcant eﬀect of EPA on cardiac adverse events such as POAF was 
observed.  However,  our results clearly demonstrated that both the neutrophil-to-lymphocyte ratio and 
the 2nd-line antibiotic requirement in the EPA group were signiﬁcantly decreased compared to the 
untreated control group (p＜0.05).  We suggest that EPA administration may exert anti-inﬂammatory 
eﬀects in patients with hyperlipidemia and in those undergoing cardiac surgery,  possibly through an 
increase in plasma adiponectin levels.
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meat and oil,  has been shown to have many beneﬁcial 
eﬀects.  Accumulated studies have shown that PUFAs 
such as eicosapentaenoic acid (EPA) have protective 
properties against cardiovascular disease (CVD) [1-3].  
A high intake of PUFAs was suggested as one possi-
ble reason for the relatively low prevalence of CVD in 
Japan [4].  EPA treatment prevented and reversed 
insulin resistance in high-fat diet-induced obese mice 
via adipose tissue inﬂammation,  and an increase in the 
EPA/arachidonic acid (AA) ratio was reported to be 
associated with improved arterial stiﬀness in obese 
patients with dyslipidemia [5].  The mechanisms 
underlying these beneﬁcial eﬀects are based on inter-
ference with the AA cascade that produces pro-
inﬂammatory eicosanoids,  the formation of novel bio-
active lipid mediators,  and changes in the pattern of 
adipocytokine secretions [6].
　 The dysregulation of pro- and anti-inﬂammatory 
adipocytokine production is associated with the meta-
bolic syndrome,  suggesting that inﬂammatory changes 
in obese adipose tissue may critically contribute to the 
development of many aspects of the metabolic syn-
drome,  which can progress to diabetes and athero-
sclerosis.  Among many adipocytokines,  adiponectin is 
unique in that it is the only established adipocytokine 
with antiatherogenic and anti-inﬂammatory properties 
[7,  8].  Adiponectin also increases tissue fat oxida-
tion,  leading to reduced levels of fatty acids and tissue 
triglyceride content,  thus enhancing insulin sensitivity 
in the liver and skeletal muscle [9,  10].  Because 
plasma adiponectin concentrations are decreased in 
obese subjects [11],  extensive research has been 
conducted to investigate the upregulation of adiponec-
tin and its cognate receptors for the treatment of 
obesity-related metabolic sequelae [7].
　 Cardiac surgery (including cardiopulmonary bypass 
[CPB]) initiates a systemic inﬂammatory response 
syndrome (SIRS) that may lead to considerable post-
operative mortality as well as complications.  This 
syndrome arises mainly due to contact between the 
blood and the artiﬁcial surfaces of the bypass circuit 
[12-14].  Attempts to prevent this inﬂammatory 
response following cardiac surgery by pharmacological 
means are warranted,  because a reduction in the 
inﬂammatory response may contribute to the protec-
tion of organ function and hence to improved recovery 
from surgical revascularization procedures.  Adipose 
tissue secretes both pro-inﬂammatory cytokines such 
as interleukin-6 (IL-6) and anti-inﬂammatory media-
tors such as adiponectin.  Inﬂammation has been 
implicated in the pathogenesis of postoperative cardiac 
adverse events such as postoperative atrial ﬁbrillation 
(POAF).  We previously reported that a daily preop-
erative administration of pentoxifylline (PTX) con-
tributed to the attenuation of CPB-induced SIRS 
through the reduction of serum IL-6 levels [15].
　 In the present study,  we sought to determine 
whether the administration of EPA could increase 
plasma EPA levels and also to clarify the association 
between EPA administration and adiponectin produc-
tion in patients with hyperlipidemia.  We also attempted 
to assess the eﬀect of preoperative EPA administra-
tion on postoperative adverse events such as POAF 
and postoperative infection in patients who underwent 
cardiac surgery.  Because in previous studies the 
group of patients with postoperative infections had 
signiﬁcantly lower adiponectin levels throughout the 
perioperative period than the uninfected group [16-
19],  the present study provides important insight into 
the therapeutic implications of EPA treatment in 
patients with hyperlipidemia and/or cardiac surgery.
Patients and Methods
　 Clinical research I. We randomly separated 
60 hyperlipidemic patients (total cholesterol＞220 
mg/dL) into an experimental group of 31 patients and 
a control group of 29 patients.  The patients (31 
males,  29 females) were aged 54 to 84 yrs (median 
71 yrs),  and they had all been treated at cardiovascu-
lar outpatient clinic in Fukuyama Medical Center in 
the 3-yr period from January 2010 to February 2013.  
These patients had a history that included hyperten-
sion,  coronary heart disease,  arrhythmia,  chronic 
heart failure,  diabetes mellitus and hyperlipidemia.  
None of the patients had a history that included can-
cer,  signiﬁcant systemic disease,  history of inﬂamma-
tory disease,  and serum creatinine greater than 
2.0mg/dL.  Their hyperlipidemic status was diagnosed 
according to fasting serum total cholesterol_＞220 
mg/dL.  The experimental group received EPA 900mg 
daily for 3 to 6 months (EPA group),  and the control 
group did not receive EPA.  The study protocol was 
approved by the Fukuyama Medical Center Trust 
Ethics Committee.  Written informed consent was 
obtained from all patients.
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　 Clinical data were obtained upon admission.  The 
patientsʼ demographic data,  medical history and medi-
cation for hyperlipidemia,  hypertension,  diabetes 
mellitus (DM),  prior coronary heart disease (CHD) 
and current smoking status were recorded.  Hyper-
tension was deﬁned as systolic blood pressure of 
140mmHg or more and/or diastolic blood pressure of 
90mmHg or more,  and the use of antihypertensive 
therapy.  DM was deﬁned as recurrent or persistent 
hyperglycemia,  and was diagnosed when the patient 
demonstrated any one of the following: fasting plasma 
glucose level＞126mg/dL,  plasma glucose levels＞200 
mg/dL 2h after a 75-g oral glucose load,  as in a 
glucose tolerance test,  and symptoms of hyperglyce-
mia and casual plasma glucose＞200mg/L.  Each 
patientʼs height and body weight were measured,  and 
the body mass index (BMI) was calculated.  Obesity 
was deﬁned as a BMI＞25.  The criteria used for a 
diagnosis of CHD were an old myocardial infarction 
and angina pectoris based on the patientʼs clinical his-
tory,  electrocardiogram and myocardial scintigraphy 
or coronary angiography ﬁndings.  The patientʼs clini-
cal characteristics and drug administration status are 
summarized in Table 1.
　 Blood samples were collected in the morning after 
an overnight fast and examined.  The concentrations of 
triglyceride (TG),  high-density lipoprotein-choles-
terol (HDL-C),  and low-density lipoprotein-choles-
terol (LDL-C) were measured enzymatically on an 
autoanalyzer (Hitachi 7600-110; Hitachi High-
Technologies,  Tokyo) using reagent kits from Daiichi 
Pure Chemicals (Tokyo).  Fasting blood glucose (FBG) 
was measured on ABL 700 analyzer (Radiometer 
Medical A/S,  Copenhagen,  Denmark).  The serum 
concentrations of insulin were measured by a chemilu-
minescence immunological assay.  Homeostasis model 
assessment of insulin resistance (HOMA-IR) was cal-
culated with the following formula: [fasting insulin 
(µU/mL)]×[fasting glucose (mg/dL)]/405.  We deter-
mined the serum levels of HbA1c by conducting ionic 
exchange high-pressure liquid chromatography with 
commercial products.
　 We measured the serum levels of visfatin C using 
Visfatin C-terminal (Human) EIA kit (Phoenix 
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Table 1　 Clinical characteristics of the EPA and Control group patients with hyperlipidemia
EPA group (n＝31) Control group (n＝29) p
Age (years) 71.0±8.4 70.5±7.9 ns
Sex (male %) 18 (58.1) 13 (44.8) ns
BMI (kg/m2) 25.0±4.5 25.7±3.9 ns
CHD (%) 17 (54.8) 11 (37.9) ns
Hypertension (%) 28 (90.3) 27 (93.1) ns
DM (%) 12 (38.7) 12 (41.4) ns
Current smoker (%) 1 (3.2) 0 (0) ns
Drug treatment
　Lipid-lowering therapy
　　Statins (%) 22 (71.0) 20 (69.0) ns
　　Fibrates (%)  7 (22.6)  7 (24.1) ns
　Antihypertensive therapy
　　CCB (%) 18 (58.1) 19 (65.5) ns
　　ACEI/ARB (%) 23 (74.2) 22 (75.9) ns
　　Diuretics (%)  9 (29.0)  7 (24.1) ns
　　β blocker (%) 14 (45.2) 14 (48.3) ns
　Oral hypoglycemic agent
　　SU (%) 3 (9.7)  3 (10.3) ns
　　α-GI (%)  4 (12.9)  6 (20.7) ns
　　Metformin (%)  5 (16.1) 0 (0) ns
　　Pioglitazone (%)  6 (19.3)  4 (13.8) ns
BMI,  body mass index; CHD,  coronary heart disease; DM,  diabetes mellitus; CCB,  calcium channel blocker; ACE-I,  angiotensin con-
verting-enzyme inhibitors; ARB,  angiotensin II type I receptor blockers; SU,  sulfonyl urea; α-GI,  α-glucosidase inhibitor; ns,  not signiﬁ-
cant.
Pharmaceuticals,  Burlingame,  CA,  USA).  Predictors 
of adiponectin and leptin were measured using com-
mercially available kits.  The serum levels of high 
sensitivity C-reactive protein (Hs-CRP) were deter-
mined using an Auto CRP MX type (Nissui Seiyaku,  
Tokyo,  Japan).
　 Statistical analysis. We used a repeated-
measures analysis of variance (ANOVA) (control and 
EPA-treated groups x before and after the treatment) 
to access the comparative eﬀect of EPA treatment on 
the measured variables.  All data are expressed as the 
mean ± standard deviation (SD) or standard error 
(SE).  The post-EPA treatment values were calculated 
as the values relative to the pre-EPA treatment val-
ues.  A two-tailed,  paired t-test was applied for the 
evaluation of changes from baseline conditions to those 
at 3-6 months.  Comparisons of the means between the 
two groups at base line or post-treatment were per-
formed using Studentʼs t-test.  The changes from 
baseline conditions to those at 3-6 months are abbre-
viated as△.  We performed a stepwise multivariate 
regression analysis using a model in which the depen-
dent variable was adiponectin,  with the following 
explanatory variables: leptin,  visfatin,  FBG,  insulin,  
HOMA-IR,  HbA1c,  LDL-C,  HDL-C,  TG,  eGFR,  
Hs-CRP and the treatment with EPA.  All statistical 
analyses were performed using the Stat View program 
version 5.0 for Windows (SAS Institute,  Cary,  NC).
　 Clinical research II. Patients requiring car-
diac surgery were enrolled in this study.  The exclu-
sion criteria included recent history of atrial ﬁbrilla-
tion or arrhythmia,  and treatment with anti-arrhythmic 
agents (e.g.,  β-blocker),  nonsteroidal anti-inﬂamma-
tory drugs (NSAIDs) or steroids.  Pacemaker users 
were also excluded.  We randomly divided the 22 
patients into an experimental group of 10 patients and 
a control group of 12 patients.  The patients (13 
males,  9 females) were aged 54 to 86 yrs (median 
70.5 yrs),  and treated at Iwakuni clinical center from 
February 2013 to March 2014.  The diagnoses were 8 
angina pectoris (36ｵ),  7 aortic valve stenosis (32ｵ),  
5 mitral valve regurgitation (23ｵ),  others (9ｵ).  
None of the patients had a history undergoing cardiac 
surgery.  The experimental (EPA) group received an 
oral EPA administration of 1,800mg/day,  and the 
Control group did not.  In the EPA group,  the EPA 
administration was started on preoperative day 31 and 
was continued for 1 months.  All patients gave their 
written consent before being enrolled in the study,  
which was approved by the Iwakuni Medical Center 
Trust Ethics Committee.  Written informed consent 
was obtained from all patients.
　 An anthropometric examination of the patients was 
performed.  All patients were measured and weighed.  
Their clinical characteristics,  diagnoses,  risk factors 
and operative procedures are summarized in Table 2.  
The serum fatty acid composition including compo-
nents such as EPA and AA was determined by the gas-
chromatography method (SRL,  Tokyo).  The determi-
nation of other various other serum parameters was 
accomplished as described in above for Clinical 
Research I.  The patientʼs urine levels of cathecholamines 
were measured by radioassay using the TOSOH CA 
test by high-performance liquid chromatography down-
stream promoter element (HPLC-DPE) technique 
(SMS,  Tokyo),  and their urine levels of cortisol were 
determined using the Chemilumi ACS-E Cortisol 
CLIA kit by Chemilumi ADVIA Centaur (Siemens 
Healthcare Diagnostics,  Malvern,  PA).  Patients 
proﬁles and the pre-,  peri-and postoperative clinical 
data for both groups are listed in Table 3.
　 Statistical analysis. The statistical analysis of 
the Clinical Research II results was performed using 
PASW Statistics 18.0 (SPSS,  Chicago,  IL,  USA).  
Fisherʼs exact tests were performed to assess the 
univariate analysis of the categorical data,  and 
Studentʼs t-test was used to assess the quantitative 
data.  P-values＜0.05 were considered signiﬁcant.
Results
　 Comparison of clinical proﬁ les and pretreat-
ment data of various parameters in the EPA and 
the Control groups of hyperlipidemic patients.
There were no signiﬁcant diﬀerences in the patientsʼ 
proﬁles (i.e.,  sex,  age,  BMI,  surgical stress,  surgical 
procedures,  CHD,  hypertension,  DM,  drug adminis-
tration status) between the EPA group and the 
Control group (Table 1).  As shown in Table 3,  no 
signiﬁcant diﬀerences were also observed in the pre-
treatment data of various parameters between the two 
groups except for the TG value: EPA group 177.3±
78.1mg/dL,  Control group 120.2±42.2 (p＜0.05).
　 Eﬀ ect of EPA administration on various 
parameters in the hyperlipidemic patients.
The preoperative EPA administration signiﬁcantly 
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increased the patientsʼ serum concentration of EPA by 
approximately twofold (p＜0.001) relative to the 
baseline values,  resulting in a signiﬁcant increase in 
the EPA/AA ratio (p＜0.001).  The EPA treatment 
also signiﬁcantly increased the serum levels of adi-
ponectin (p＜0.05).  The insulin resistance,  deter-
mined by the HOMA-IR,  was signiﬁcantly improved in 
the EPA group (p＜0.05),  but not in the Control 
group.  In addition,  the level of Hs-CRP in the EPA 
group was signiﬁcantly decreased (p＜0.05).  No signiﬁ-
cant changes in the serum levels of leptin,  visfatin,  
LDL-C,  HDL-C,  and TG were observed in either 
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Table 2　 Pre-operative demographic characteristics of the 22 EPA group and Control group patients undergoing cardiac surgery
EPA group (n＝10) Control group (n＝12) p
Age (years) 71.6±4.8 69.6±8.6 ns
Height (cm) 156.6±9.5 158.2±5.3 ns
Weight (kg) 54.7±14.6 56.1±8.7 ns
Sex (Male/Female) 4/6 9/3 ns
Diagnosis
　Angina pectoris 5/10 3/12 ns
　Aortic valve stenosis 2/10 5/12 ns
　Aortic valve regurgitation 1/10 0/12 ns
　Mitral valve regurgitation 1/10 4/12 ns
　Ventricular septal defect 1/10 0/12 ns
NYHA
　ClassⅠ 4/10 7/12 ns
　ClassⅡ 6/10 5/12 ns
　ClassⅢ 0/10 0/12 ns
　ClassⅣ 0/10 0/12 ns
EF 60.0±10.4 68.3±7.9 ns
Normal LVF (.50%) 7/10 12/12 ns
Risk factors
　Hyperlipidemia 4/10 8/12 ns
　Hypertension 9/10 10/12 ns
　Smoking 5/10 7/12 ns
　Obesity 1/10 2/12 ns
　Peripheral arterial disease 1/10 0/12 ns
Serum levels
　Creatinine (mg/dL) 0.97±0.37 0.95±0.28 ns
　CK-MB (＞25 IU/mL) 0/10 0/12 ns
　CRP (＞1.0mg/dL) 1/10 0/12 ns
Insulin (µU/mL) 15.4±14.6 14.2±19.3 ns
HOMA-IR 4.2±3.6 3.6±4.4 ns
FBG (mg/dl)  120.4±34.4  111.3±19.2 ns
Operation
　Operation Time (min) 191.3±40.3 226.7±53.1 ns
　Blood Loss (mL) 516.3±298.5 287.0±222.9 ns
　Surgical Procedure OPCAB : 5 OPCAB : 3
AVR : 3 AVR : 5
MVP : 1 MVP : 2
VSD closure : 1 MVR : 2
OPCAB,  oﬀ pump CABG; CABG,  coronary artery bypass grafting; AVR,  aortic valve replacement; MVP,  mitral valve plasty; MVR,  mitral 
valve replacement; VSD,  ventricular septal defect.
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Table 3　 Pretreatment data of various parameters of the EPA and Control group patients with hyperlipidemia
EPA group (n＝31) Control group (n＝29) p
EPA (µg/mL) 83.0±52.6 73.2±37.2 ns
AA (µg/mL) 185.1±63.0 164.7±49.8 ns
EPA/AA 0.4±0.3 0.5±0.2 ns
Adiponectin (µg/mL) 10.4±7.1 14.5±3.5 ns
Leptin (ng/mL) 10.8±9.7 11.1±7.0 ns
Visfatin (ng/mL) 6.4±1.3 6.50±1.17 ns
FBG (mg/dL) 112.4±21.7 106.9±15.6 ns
Insulin (µU/mL) 9.3±5.3 8.2±5.6 ns
HOMA-IR 2.9±1.8 2.3±1.8 ns
HbA1C (%) 5.8±0.9 5.6±0.5 ns
LDL-C (mg/dL) 122.5±32.0 117.0±25.4 ns
HDL-C (mg/dL) 52.6±12.7 57.9±11.4 ns
LDL-C/HDL-C 2.5±1.1 2.1±0.6 ns
Triglyceride (mg/dL) 177.3±78.1 120.2±42.2 P＜0.05
eGFR (ml/min/1.73m2) 63.2±16.2 62.4±19.0 ns
Hs-CRP (mg/dL) 0.3±0.4 0.2±0.3 ns
 (mean±SD)
FBG,  fasting blood glucose; LDL-C,  low-density lipoprotein cholesterol; HDL-C,  high-density lipoprotein cholesterol; HOMA-IR,  homeo-
stasis model assesment of insulin resistance; eGFR,  estimated glomerular ﬁltration rate; EPA,  eicosapentaenoic acid; AA,  arachidonic 
acid; Hs-CRP,  high sensitivity C-reactive protein.
Table 4　 The eﬀect of EPA on various parameters in the hyperlipidemic patients relative to the baseline values
EPA group (n＝31) (after/before) Control group (n＝29) (after/before)
EPA (µg/mL) 2.0±0.1＊＊ (164.1±65.7/83.0±52.6) 1.0±0.1 (69.8±34.9/73.2±37.2)
AA (µg/mL) 0.9±0.1 (173.4±56.7/185.1±63.0) 1.1±0.1 (174.2±46.3/164.7±49.8)
EPA/AA 2.3±0.2＊＊ (1.00±0.57/0.44±0.26) 1.0±0.1 (0.49±0.27/0.47±0.24)
Adiponectin (µg/mL) 1.3±0.1＊ (12.48±8.49/10.41±7.08) 1.0±0.1 (14.75±4.97/14.49±3.45)
Leptin (ng/mL) 1.1±0.2 (12.26±14.58/10.78±9.67) 1.0±0.0 (10.79±6.46/11.14±7.04)
Visfatin (ng/mL) 0.9±0.0 (6.00±1.45/6.42±1.33) 1.0±0.1 (6.52±1.69/6.50±1.17)
FBG (mg/dL) 1.0±0.0 (110.1±18.4/112.4±21.7) 1.1±0.0 (112.5±15.4/106.9±15.6)
Insulin (µU/mL) 0.8±0.1＊ (7.53±3.73/9.32±5.30) 1.1±0.1 (8.84±4.93/8.16±5.57)
HOMA-IR 0.7±0.1＊ (2.13±1.24/2.87±1.79) 1.1±0.2 (2.62±1.72/2.29±1.81)
HbA1C (%) 1.0±0.1 (5.62±0.63/5.78±0.88) 1.0±0.0 (5.52±0.41/5.60±0.53)
LDL-C (mg/dL) 0.9±0.1 (111.6±34.6/122.5±32.0) 1.0±0.0 (113.7±21.4/117.0±25.4)
HDL-C (mg/dL) 1.0±0.1 (53.9±13.3/52.6±12.7) 1.0±0.0 (60.0±10.8/57.9±11.4)
LDL-C/HDL-C 0.9±0.1 (2.18±0.81/2.50±1.10) 0.9±0.1 (1.96±0.53/2.10±0.59)
Triglyceride (mg/dL) 0.9±0.1 (148.2±49.2/177.3±78.1) 1.0±0.1 (124.7±48.3/120.2±42.2)
eGFR (ml/min/1.73m2) 1.0±0.1 (62.2±20.0/63.2±16.2) 1.0±0.1 (61.1±17.3/62.4±19.0)
Hs-CRP (mg/dL) 0.6±0.1＊ (0.17±0.17/0.29±0.42) 4.9±0.7 (0.83±0.56/0.17±0.28)
(mean±SE)
FBG,  fasting blood glucose; LDL-C,  low-density lipoprotein cholesterol; HDL-C,  high-density lipoprotein cholesterol; HOMA-IR,  homeo-
stasis model assesment of insulin resistance; eGFR,  estimated glomerular ﬁltration rate; EPA,  eicosapentaenoic acid; AA,  arachidonic 
acid; Hs-CRP,  high sensitivity C-reactive protein; ＊p＜0.05,  ＊＊p＜0.001
groups (Table 4).
　 Eﬀ ect of EPA on adiponectin, HOMA-IR and 
CRP in the hyperlipidemic patients. To deter-
mine the risk factors independently inﬂuencing the 
changes of plasma adiponectin and HOMA-IR,  we 
performed stepwise multivariate regression analyses,  
the results of which are shown in Supplemental Tables 
S3 and S4.  This analysis revealed EPA treatment as 
a factor that increased the plasma adiponectin concen-
trations and decreased the HOMA-IR (Table 5).
　 The clinical proﬁ les of the EPA and Control 
group patients undergoing with cardiac surgery.
There were no signiﬁcant diﬀerences in age,  weight,  
sex,  surgical stress or surgical procedures between 
the Control and EPA groups.  In addition,  no signiﬁ-
cant diﬀerences were found between the groups in 
their preoperative hemodynamic data or in the number 
of risk factors for cardiovascular surgery (Table 2).
　 Eﬀ ect of EPA administration on the postop-
erative course. The preoperative EPA treatment 
signiﬁcantly increased the patientsʼ plasma EPA levels 
(p＜0.001) and signiﬁcantly decreased their AA levels 
(p＜0.02),  resulting in signiﬁcantly decreased EPA/
AA ratios (p＜0.001) compared to the Control group.  
However,  the insulin resistance as designated by the 
plasma levels of insulin/FBS and HOMA-IR was not 
signiﬁcantly improved in the EPA group.  No signiﬁ-
cant diﬀerences in various other postoperative param-
eters including the length of intensive care unit (ICU) 
and hospital stay were observed between the two 
groups.  In addition,  there were no signiﬁcant diﬀer-
ences in postoperative adverse events between the 
groups (Table 6).
　 Eﬀ ect of EPA administration on postopera-
tive white blood cells counts and antibiotics 
requirement. The neutrophil counts at postopera-
tive days (PODs) 1 and 3 in the EPA group were 
signiﬁcantly lower than those in the Control group (p
＜0.05),  respectively.  In contrast,  no signiﬁcant dif-
ferences were observed in the lymphocyte counts 
between the groups throughout the observation period.  
In addition,  the neutrophil to lymphocyte ratios 
(NLR) at PODs 1 and 3 in the EPA group were sig-
niﬁcantly decreased compared to those in the Control 
group (p＜0.05),  respectively (Table 7).  The EPA 
pretreatment signiﬁcantly decreased the requirement 
for a 2nd-line antibiotic (p＜0.05) (Table 7).
Discussion
　 The present studyʼs results revealed that the EPA 
administration signiﬁcantly increased the serum levels 
of EPA and the EPA/AA ratio in patients with 
hyperlipidemia and in those undergoing cardiac sur-
gery.  The results also showed a signiﬁcant concomi-
tant increase in the serum levels of adiponectin in the 
hyperlipidemic patients.  Our ﬁndings suggested that a 
signiﬁcant increase in the plasma EPA level could 
increase adiponectin production in humans,  which is 
consistent with previous reports that EPA increased 
adiponectin production in adipocytes and in mice [20-
25].
　 The mechanism by which PUFAs modulate adi-
ponectin secretion is not fully understood.  Several 
studies indicated that EPA increases the adiponectin 
concentration in 3T3-L1 adipocytes and prostaglan-
dins (PGs) of the 3-series formed from EPA increase 
the secretion of adiponectin,  in part through a PPAR-
γ-dependent mechanism [20-25].
　 Previous studies demonstrated that adiponectin has 
insulin-sensitizing properties as well as anti-inﬂamma-
tory and anti-atherogenic properties [26,  27].  In the 
present study,  EPA administration signiﬁcantly 
decreased the serum insulin level and HOMA-IR index 
of hyperlipidemic patients,  indicating that the EPA 
administrations improved insulin resistance,  as was 
previously clariﬁed in several animal models of obesity 
and diabetes [28].  Our stepwise multivariate regres-
sion analyses (using the variables shown in Table 1) 
clearly demonstrated that only the treatment with EPA 
was an independent determinant of plasma adiponectin 
concentrations and HOMA-IR in the hyperlipidemic 
patients (Table 5).  Therefore,  the improvement of 
insulin resistance in EPA-treated patients with hyper-
lipidemia is possibly through EPA-induced adiponectin 
secretion.
　 We also found that EPA treatment signiﬁcantly 
lowered the plasma level of Hs-CRP in hyperlipidemic 
patients (Table 4).  This anti-inﬂammatory property of 
the EPA treatment was conﬁrmed by the results of the 
stepwise multivariate regression analyses,  which 
showed that the EPA treatment was associated nega-
tively with ∆CRP (Table 5).  This result also indicates 
that the observed anti-inﬂammatory eﬀect in the EPA-
treated hyperlipidemic patients also occurred via a 
plasma adiponectin increase.  These results are consis-
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Table 6　 The eﬀect of EPA on various parameters including postoperative adverse events
EPA group (n＝10) Control group (n＝12) p
One Day before Operation
　EPA (µg/mL) 250.1±83.1 122.0±49.8 p＜0.001
　AA (µg/mL) 93.0±13.1 103.1±13.8 p＜0.05
　EPA/AA 2.7±0.5 1.2±0.4 p＜0.001
Insulin (µU/mL) 10.9±12.3 5.0±4.0 ns
HOMA-IR 3.5±4.8 1.1±0.9 ns
FBG (mg/dl) 107.5±38.2 93.0±11.4 ns
Post Operative Day 1
　Catecholamine requirement 4/10 4/12 ns
　CRP(mg/dL) 3.1±1.9 3.2±1.9 ns
　SOFA score 3.3±2.0 4.3±1.6 ns
　Adrenalin (µg/L) 328.1±300.4 169.2±107.3 ns
　Noradrenalin (µg/L) 175.1±207.1 120.8±65.0 ns
　Dopamine (µg/L) 486.2±784.9 1092.1±1887.5 ns
　Cortisol (µg/L) 3827.8±3998.3 2050.7±999.7 ns
Length of ICU stay (days) 2.3±0.6 2.0±0 ns
Length of Hospital stay (days) 29.3±5.4 30.1±7.4 ns
Adverse events
　Antiarrhythmic agent (other than β-blockers) 0/10 0/12 ns
　Delayed tamponade 0/10 2/12 ns
　gastrointestinal bleeding 0/10 0/12 ns
　TIA 0/10 0/12 ns
　AF 3/10 4/12 ns
(mean±SD)
SOFA,  sequential organ failure assessment; TIA,  transient ischemic attacks; AF,  atrial ﬁbrillation.
Table 5　 Stepwise multivariate regression analyses for changes in plasma adiponectin and HOMA-IR after EPA treatment in hyperlipi-
demic patients
(1) Plasma adiponectin
Partial regression coeﬃcient Standardized partial regression coeﬃcient P value 95% conﬁdence interval
Constant －0.93 　0.37 －3.01 1.15
EPA treatment 　3.14 0.33 　0.04 　0.09 6.19
ΔCRP －2.61 0.39 　0.02 　0.45 4.77
(2) HOMA-IR
Partial regression coeﬃcient Standardized partial regression coeﬃcient P value 95% conﬁdence interval
Constant －0.25 　0.34 －0.79 0.28
EPA treatment －1.07 0.41 　0.01 　0.32 1.83
ΔCRP 　0.72 0.39 　0.01 　0.19 1.23
ΔCRP: changes from baseline C-reactive protein (CRP) to those at 3 months.
tent with previous reports that the eicosanoids derived 
from EPA have less inﬂammatory activities compared 
to those of AAs [29-31],  and the beneﬁcial eﬀects of 
PUFAs may be attributable to the modulation of adi-
pocytokine secretion [32,  33].
　 Adiponectin is also known to exert a regulatory 
role in atherogenesis.  A recent study demonstrated 
that the adiponectin concentrations in the serum and 
peri-coronary fat of patients without coronary artery 
disease (CAD) were signiﬁcantly higher than those of 
patients with CAD [34].  In addition,  the imbalance 
of adipocytokine signals in the epicardial adipose tis-
sue was strongly linked to human coronary atheroscle-
rosis [35].  There is also a report that the level of 
adiponectin mRNA in the epicardial adipose tissue in 
patients with CAD was also signiﬁcantly lower than in 
patients without CAD [36].  Another group suggested 
that a low adiponectin level may contribute to a higher 
incidence of postcardiac surgery atrial ﬁbrillation in 
obese patients [37].  We found previously that serum 
adiponectin levels were negatively associated with 
obesity and CAD [38].  Obesity is an independent risk 
factor for CVD and promotes CVD risk.  Bariatric 
surgery has gained favor because it ameliorates CVD,  
and the underlying mechanism was proposed to be 
through the modulation of adipokine secretion [39].
　 Together the above-cited reports provide extensive 
evidence in humans and in mouse and in vitro models of 
the cardioprotective eﬀects of adiponectin,  and it 
would seem that adiponectin is a promising marker for 
the monitoring of cardiovascular risk factors.  Atrial 
ﬁbrillation is the most common postoperative arrhyth-
mia,  with signiﬁcant consequences on patient health.  
POAF complicates up to 8ｵ of all noncardiac surger-
ies,  3ｵ～30ｵ of noncardiac thoracic surgeries,  and 
16ｵ～46ｵ of cardiac surgeries.  POAF has been 
associated with increased morbidity,  and mortality,  
and longer,  more costly hospital stays [40].  It was 
reported that cardiac surgery signiﬁcantly increased 
both the insulin and blood glucose levels of the 
patients,  resulting in the postoperative development of 
insulin resistance [41].  The results of our clinical 
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Table 7　 The eﬀect of EPA on WBC counts and antibiotics requirement
EPA group (n＝10) Control group (n＝12) p
WBC counts
　neutrophils（/µL）
　　　POD 1 9,712±194 12,045±164 p＜0.05
　　　POD 3 9,183±287 12,728±418 p＜0.05
　　　POD 7 5,245±149 7,205±246 ns
　lymphcyte（/µL）
　　　POD 1 790±58 781±97 ns
　　　POD 3 1,333±213 1,214±315 ns
　　　POD 7 1,766±149 1,977±228 ns
　Neutrophil to lymphocyte ratio (NLR)
　　　POD 1 13.3±4.7 17.1±6.2 p＜0.05
　　　POD 3 8.2±4.0 13.7±5.9 p＜0.05
　　　POD 7 3.3±1.4 4.4±2.6 ns
Anitbiotics requirement
　prophylatic
　　　sulbactam sodium/amikacin sulfate 10/10 12/12 ns
　2nd line 1/10 4/12 p＜0.05
　　　sulbactam sodium 0 1 ns
　　　sulbactam sodium/amikacin sulfate 0 1 ns
　　　meropenem hydrate 1 0 ns
　　　vancomycin hydrochloride 0 2 ns
Type of infection
　　　pneumonia 0 4 －
　　　urinary tract infection 1 0 －
(mean±SD)
POD,  post operative day.
research I study clariﬁed that the EPA administration 
enhanced adiponectin production and improved insulin 
resistance in patients with hyperlipidemia.  Based on 
that result,  we designed the Clinical Research II study 
to evaluate the impact of preoperative EPA adminis-
tration on patients with cardiac surgery.
　 However,  no signiﬁcant diﬀerences were observed 
between the EPA and Control groups regarding the 
parameters of catecholamine requirement,  CRP,  
Sequential Organ Failure Assessment (SOFA) score,  
stress hormone,  length of ICU stay,  length of hospital 
stay,  insulin resistance and cardiac adverse events 
such as POAF,  although the EPA pretreatment sig-
niﬁcantly increased the plasma EPA levels and AA 
levels (Table 6).  The postoperative eﬀect of EPA on 
cardiac surgery patients have been controversial.  
There is evidences that the treatment of infants 
undergoing CPB with a lipid emulsion containing EPA 
improved fatty acid status and resulted in a lower 
inﬂammatory response after cardiac surgery [42].  In 
addition,  a recent study demonstrated that periopera-
tive EPA infusions signiﬁcantly increased EPA con-
centrations in platelet and atrial tissue membranes 
within 12h of the ﬁrst EPA administration and 
decreased biological and clinical signs of inﬂammation,  
suggesting that peri- operative EPA might be beneﬁ-
cial in elective cardiac surgery with CPB [43].  In 
contrast,  it was reported that treatment with EPA had 
no eﬀect on the incidence of POAF in patients under-
going open heart surgery [44],  and that neither 
higher habitual circulating PUFAs levels nor achieved 
levels or changes following short-term ﬁsh oil supple-
mentation were associated with the risk of POAF 
[45].
　 Our present data do not support the beneﬁcial 
eﬀects of EPA on cardiac adverse events.  This may 
be attributable to the selection of patients.  None of 
the cardiac surgery patients enrolled in this study 
were hyperlipidemic,  and the obese patients in the 
EPA and the Control groups were only 10.0ｵ (1/10) 
and 16.7ｵ (2/12),  respectively.  In addition,  all of the 
cardiac surgery patients were diagnosed as Class I or 
II by the NYHA classiﬁcation (Table 2).  To better 
test the data of pre-operative EPA treatment on car-
diac adverse events,  future studies should include 
high-risk patients with hyperlipidemia,  obesity,  DM 
and NYHA III or IV.
　 However,  we found that the pre-EPA treatment 
signiﬁcantly decreased the neutrophil to lymphocyte 
ratio (NLR) values (Table 6).  Recent research clearly 
demonstrated that the NLR was associated with 
severe,  extensive and complex CAD and could be used 
to predict the presence of moderate to severe involve-
ment prior to CAD with a quite satisfactory sensitiv-
ity and speciﬁcity [46].  It was also reported that the 
NLR was a useful marker to predict subsequent,  
mortality in patients admitted for myocardial infarc-
tion with ST-segment elevation [47,  48].  Several 
studies found that cardiovascular mortality was sig-
niﬁcantly higher in an elevated-NLR group compared 
to a low-NLR group [49-51].  The NLR has thus 
attracted attention as an easily obtained marker of 
inﬂammation [52,  53].
　 Mechanistically,  neutrophils are known to induce 
plaque disruption by releasing proteolytic enzymes and 
superoxide radicals.  They contribute to the plugging 
of microvessels and cause myocardial ischemia [54,  
55].  In light of this,  we suspect that pre-operative 
EPA treatment could be a novel therapy for the eﬀec-
tive prevention of postoperative adverse events,  even 
though in the present study we did not observe a posi-
tive eﬀect of EPA on patients undergoing cardiac 
surgery.  There have been reports that the NLR is a 
prognostic aid for conditions other than cardiac 
events,  such as for the prognosis in cancer-burden 
patients [56-59],  suggesting that the NLR indicates 
the status of cell-mediated immunity.
　 In the present study of patients undergoing cardiac 
surgery,  the pre-operative EPA treatment signiﬁ-
cantly increased the plasma EPA levels,  resulting in 
an increase in plasma adiponectin levels and signiﬁ-
cantly decreasing the NLR.  The plasma levels of 
adiponectin and the NLR were thus negatively associ-
ated.  Previous studies showed that patients with a 
postoperative infection had signiﬁcantly lower adi-
ponectin levels throughout the perioperative period 
than the uninfected group [16,  17],  indicating that 
preoperative adiponectin levels may be useful for 
anticipating the development of a postoperative infec-
tion.
　 In addition,  recent research demonstrated that 
plasma adiponectin was decreased in septic patients 
and negatively correlated with the SOFA score,  and 
that the plasma adiponectin levels of survivors with 
sepsis was gradually increased and the levels in non-
survicors was decreased [18,  19].  Our present ﬁnd-
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ings showed that the requirement of 2nd-line antibiot-
ics in the EPA group was signiﬁcantly decreased 
compared to that of the Control group (Table 6),  
indicating that the preoperative EPA administration 
might decrease the incidence of bacterial infections 
following cardiac surgery,  possibly through the 
increase in the plasma adiponectin level.
　 Adipose tissue is well known to secret both pro-
inﬂammatory cytokines such as IL-6 and anti-inﬂam-
matory mediators such as adiponectin.  It was sug-
gested that increased epicardial adipose tissue may 
play a pivotal role in the development of coronary 
disease through the impairment of adiponectin secre-
tion [60].  Inﬂammatory responses triggered by obe-
sity,  hyperlipidemia and surgical stress have been 
implicated in the pathogenesis of arrhythmia,  and 
increased epicardial adiponectin may thus contribute 
to the maintenance of sinus rhythm [61,  62].  The 
protective eﬀects of adiponectin on coronary artery 
diseases were described as being attributable to 
adiponectinʼs anti-inﬂammatory,  anti-atherogenic and 
insulin-sensitizing properties by inhibiting macrophage-
mediated inﬂammation [63-66].
　 In conclusion,  our present results demonstrated 
that EPA administration could increase plasma EPA 
levels,  resulting in increased plasma adiponectin levels 
in patients with hyperlipidemia and in patients who are 
undergoing a cardiac surgery.  This adiponectin increase 
might be associated,  at least in part,  with a decrease 
in the NLR,  resulting in a decreased risk of postop-
erative infection through enhanced cell-mediated 
immunity in patients undergoing cardiac surgery.  
Although we did not observe positive eﬀects of EPA 
treatment on adverse events such as POAF in the 
patients undergoing cardiac surgery,  the protective 
eﬀects of EPA on cardiovascular events cannot be 
denied in obese and＞NYHA 3 patients through an 
improved adiponectin imbalance.  Our results thus 
provide important insights into the therapeutic impli-
cations of EPA administration in patients with hyper-
lipidemia and those who will undergo cardiac surgery.  
Further research is warranted to clarify the protec-
tive eﬀects of EPA against cardiac adverse events in 
large-scale studies and in elective patients.
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